Cargando…

Cost‐effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK

INTRODUCTION: The economic and clinical burden of haemophilia A is high. Primary prophylaxis with factor VIII replacement therapy is the recognised standard of care, but the emergence of non‐factor therapies, such as emicizumab, is extending treatment options for people with haemophilia A. AIM: Ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kragh, Nana, Tytula, Anna, Pochopien, Michał, Aballéa, Samuel, Toumi, Mondher, Hakimi, Zalmai, Nazir, Jameel, Bystrická, Linda, Fatoye, Francis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107896/ https://www.ncbi.nlm.nih.gov/pubmed/36398467 http://dx.doi.org/10.1111/ejh.13901

Ejemplares similares

S300: ASSESSMENT OF JOINT HEALTH IN PATIENTS RECEIVING PROPHYLAXIS FOR HAEMOPHILIA A IN FIVE EUROPEAN COUNTRIES: A CROSS-SECTIONAL SURVEY
por: De la Corte‐rodriguez, Hortensia, et al.
Publicado: (2023)

Improvement in pain-related quality of life in patients with hemophilia A treated with rFVIIIFc individualized prophylaxis: post hoc analysis from the A-LONG study
por: Pasi, John, et al.
Publicado: (2022)

Elicitation of Health-related Quality-of-life Concepts Associated with Overactive Bladder: A Qualitative Study
por: Hawken, Natalia, et al.
Publicado: (2016)

Cost Effectiveness of Mirabegron Compared with Tolterodine Extended Release for the Treatment of Adults with Overactive Bladder in the United Kingdom
por: Aballéa, Samuel, et al.
Publicado: (2014)

Efficacy of rFVIIIFc versus Emicizumab for the Treatment of Patients with Hemophilia A without Inhibitors: Matching-Adjusted Indirect Comparison of A-LONG and HAVEN Trials
por: Klamroth, Robert, et al.
Publicado: (2021)

Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study
por: Kiialainen, Anna, et al.
Publicado: (2022)

Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK
por: Hakimi, Zalmai, et al.
Publicado: (2018)

Recombinant factor VIII Fc for the treatment of haemophilia A
por: Hermans, Cedric, et al.
Publicado: (2021)

Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK
por: Nazir, Jameel, et al.
Publicado: (2017)

Recombinant FVIIIFc Versus BAY 94-9027 for Treatment of Patients with Haemophilia A: Comparative Efficacy Using a Matching Adjusted Indirect Comparison
por: Hakimi, Zalmai, et al.
Publicado: (2020)

Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies
por: Pochopien, Michal, et al.
Publicado: (2019)

Mapping the EORTC QLQ-C30 onto the EQ-5D-5L index for patients with paroxysmal nocturnal hemoglobinuria in France
por: Wojciechowski, Piotr, et al.
Publicado: (2023)

Low immunogenicity of emicizumab in persons with haemophilia A
por: Schmitt, Christophe, et al.
Publicado: (2021)

The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies
por: Skinner, Mark W., et al.
Publicado: (2021)

Long-term outcomes of prophylaxis with a recombinant factor VIII Fc or recombinant factor IX Fc in patients with hemophilia previously treated on demand
por: Álvarez-Román, María-Teresa, et al.
Publicado: (2023)

Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder
por: Desroziers, Katia, et al.
Publicado: (2013)

Efficacy of rFIXFc versus rIX-FP for the Treatment of Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PROLONG-9FP Trials
por: Astermark, Jan, et al.
Publicado: (2021)

Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review
por: Yeowell, Gillian, et al.
Publicado: (2018)

Utilization of Emicizumab in Acquired Factor VIII Deficiency
por: Hess, Kevin J., et al.
Publicado: (2020)

Differential humanistic and economic burden of mild, moderate and severe haemophilia in european adults: a regression analysis of the CHESS II study
por: Rodriguez-Santana, Idaira, et al.
Publicado: (2022)

Health‐related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors—Results from the HAVEN 2 study
por: Mancuso, Maria Elisa, et al.
Publicado: (2020)

The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab
por: Carcao, Manuel, et al.
Publicado: (2019)

Health-related quality of life, direct medical and societal costs among children with moderate or severe haemophilia in Europe: multivariable models of the CHESS-PAEDs study
por: Rodriguez-Santana, Idaira, et al.
Publicado: (2022)

An overview of health technology assessments of gene therapies with the focus on cost-effectiveness models
por: Pochopień, Michał, et al.
Publicado: (2021)

Study protocol for assessment of the coagulation potential of concomitantly used factor VIII concentrates in patients with haemophilia A with emicizumab prophylaxis (CAGUYAMA Study): a multicentre open-label non-randomised clinical trial
por: Takeyama, Masahiro, et al.
Publicado: (2023)

Emicizumab in acquired haemophilia A: about two clinical cases and literature review
por: Hansenne, Amandine, et al.
Publicado: (2021)

Anticoagulation for Stroke Prevention after Restoration of Haemostasis with Emicizumab in Acquired Haemophilia A
por: Al-Banaa, Kadhim, et al.
Publicado: (2021)

Exposure–Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII
por: Jonsson, Fredrik, et al.
Publicado: (2021)

A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain
por: Nazir, Jameel, et al.
Publicado: (2018)

Factor VIII companion diagnostic for haemophilia
por: Hu, Chunxiao, et al.
Publicado: (2022)

Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery
por: Jiménez‐Yuste, Victor, et al.
Publicado: (2021)

Emicizumab dose up‐titration in case of suboptimal bleeding control in people with haemophilia A
por: Schmitt, Christophe, et al.
Publicado: (2022)

Commentary on “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial” by Gautret et al
por: Toumi, Mondher, et al.
Publicado: (2020)

Allocating treatment resources for hepatitis C in the UK: a constrained optimization modelling approach
por: Han, Ru, et al.
Publicado: (2021)

A phase IV, multicentre, open‐label study of emicizumab prophylaxis in people with haemophilia A with or without FVIII inhibitors undergoing minor surgical procedures
por: Escobar, Miguel, et al.
Publicado: (2022)

Factor VIII inhibitors in hemophilia A treated with emicizumab: longitudinal follow-up of outcomes
por: Levy-Mendelovich, Sarina, et al.
Publicado: (2023)

Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real‐world experience from a large comprehensive treatment centre in the US
por: Lewandowska, Magdalena, et al.
Publicado: (2020)

Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study
por: Nolan, Beatrice, et al.
Publicado: (2020)

A scoping review on quality assessment tools used in systematic reviews and meta-analysis of real-world studies
por: Gebrye, Tadesse, et al.
Publicado: (2023)

Measuring the health-related quality of life in young children: how far have we come?
por: Germain, Nicola, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_58bhh89efnjjvakjpbagnt2qvb